Aspen’s timeline
Aspen has a proud heritage
dating back more than
160 years

1850
The commencement of
the business in Port
Elizabeth, South Africa,
which later became
Lennon Limited, the
originator company to
the Group today.

1997
Aspen Healthcare
(Pty) Limited began
trading with Stephen
Saad and Gus
Attridge as two of
the four founder
members.

1999
Aspen acquired the
pharmaceutical
business of South
African Druggists for
R2,4 billion in a
hostile take-over.

2000
Aspen commenced
construction of an Oral
Contraceptive facility at
its East London site.

2001
• Aspen Australia commenced
  trade as a start-up operation.
• Nelson Mandela officiated at the
  opening of a clinic constructed
  for the disadvantaged citizens of
  Engobo, South Africa, the first of
  the community clinics established
  under Aspen’s Corporate Social
  Investment (“CSI”) programme.

2002
• Aspen concluded a Broad-Based
  Black Economic Empowerment
  (“BBBEE”) deal with CEPPWAWU
  Investments (Pty) Limited, the
  investment arm of the trade
  union representing the majority
  of Aspen’s labour force in
  South Africa.
• Aspen’s new corporate
  identity was launched
  symbolising energy, innovation
  and nurturing.

2003
• Aspen entered into a
  fostering arrangement
  with GSK for the marketing
  and distribution of
  40 branded products into
  the South African private
  sector.
• Aspen Stavudine was
  launched – Africa’s first
generic antiretroviral
(“ARV”).

2004
• Aspen acquired FCC, the only
  South African manufacturer of
  APIs.
• Aspen acquired Infacare, the
  infant nutritional brand, from
  Dutch-based Royal Numico.
• Aspen’s multi-million Rand Port
  Elizabeth-based Unit 1 facility
  became operational.

1998
Aspen was listed on the JSE
through reverse listing into
Medhold Limited.

1997
Aspen Healthcare
(Pty) Limited began
trading with Stephen
Saad and Gus
Attridge as two of
the four founder
members.

* Closing share price at financial year-end.
2005
- Aspen extended its BBBEE ownership through the conclusion of an empowerment transaction with Imithi Investments (Pty) Limited.
- Aspen’s Unit 1 facility in Port Elizabeth became the world’s first manufacturing site to receive tentative United States Food and Drug Administration (“FDA”) approval for the production of certain generic ARVs.

2006
- Aspen secured distribution rights for a number of important ARVs from MSD, Bristol Myers Squibb, Roche and Tibotec as the Group extended its portfolio as the biggest supplier of ARVs in Africa.

2007
- Prestige Brands Incorporated entered into an agreement with Aspen for the supply of eye drops from Aspen’s Sterile facility in Port Elizabeth to the United States market.

2008
- Aspen entered the Latin American market through an investment with Strides in businesses established in Brazil, Mexico and Venezuela.
- Aspen acquired 60% of the share capital of Shelys with businesses in Kenya, Tanzania and Uganda.
- Aspen Global acquired the intellectual property rights to four GSK branded products for R2,7 billion, enabling Aspen to distribute these global brands, namely Eltroxin, Imuran, Lanoxin and Zyloric, to more than 100 countries.

2009
- Aspen concluded a series of strategic transactions with GSK worth R4,6 billion comprising the acquisition of the rights to distribute GSK’s pharmaceutical products in South Africa, the formation of The GSK Aspen Healthcare for Africa Collaboration in sub-Saharan Africa (“the Collaboration”) to market and sell pharmaceuticals in sub-Saharan Africa (“SSA”), the acquisition of eight specialist branded products for worldwide distribution and the acquisition of a manufacturing site in Bad Oldesloe, Germany.

2010

2011
- Aspen acquired the pharmaceutical business of Australian-based Sigma Pharmaceuticals Limited (“Sigma”) now Aspen Pharma Pty Limited, for R5,9 billion.

2012
- Aspen established its first subsidiary in South East Asia.
- Aspen acquired a portfolio of established GSK over-the-counter (“OTC”) products in selected territories for R2,1 billion.

2013
- The Group acquired a portfolio of 25 established prescription branded products from GSK (“classic brands”) with distribution rights in Australia effective December 2012.
- In May 2013 Aspen Australia commenced the distribution of the leading infant nutritional products in that country following the acquisition of the rights to certain intellectual property licences and the related business by the Group.

2013
- The Group acquired a portfolio of 25 established prescription branded products from GSK (“classic brands”) with distribution rights in Australia effective December 2012.
- In May 2013 Aspen Australia commenced the distribution of the leading infant nutritional products in that country following the acquisition of the rights to certain intellectual property licences and the related business by the Group.